PDF herunterladen
J Neurol Surg B Skull Base
DOI: 10.1055/a-2724-4297
Original Article

Belzutifan in Von-Hippel Lindau Associated Hemangioblastomas: A Systematic Review and Meta-Analysis

Authors

  • Kiana Juliette Yeganeh 

    1   School of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico (Ringgold ID: RIN6650)
    2   Department of Neurosurgery, Brain, and Spine, University of South Florida, Tampa, United States (Ringgold ID: RIN7831)

  • Emma Sargent

    3   College of Medicine, Florida Atlantic University, Boca Raton, United States (Ringgold ID: RIN1782)
    2   Department of Neurosurgery, Brain, and Spine, University of South Florida, Tampa, United States (Ringgold ID: RIN7831)

  • Gaddiel Ahmed

    1   School of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico (Ringgold ID: RIN6650)

  • Farina Klocksieben

    4   Research Methodology and Biostatistics Core, University of South Florida, Tampa, United States (Ringgold ID: RIN7831)

  • Elliot Pressman

    5   Department of Neurosurgery and Brain Repair, USF Health Morsani College of Medicine, Tampa, United States (Ringgold ID: RIN33697)

  • Kunal Vakharia

    6   Neurosurgery, University of South Florida, Tampa, United States (Ringgold ID: RIN7831)
Weitere Informationen
Auch verfügbar auf
 als PDF herunterladen
Preview

Introduction: Belzutifan, a selective hypoxia-inducible factor 2 alpha inhibitor, was recently approved for treating renal cell carcinoma in patients with Von Hippel-Lindau (VHL) disease. Given the lack of effective systemic therapies for VHL-associated hemangioblastomas (HBs), we conducted a systematic review and meta-analysis to evaluate its efficacy in this patient population. Methods: Scientific databases and clinical trial registries were systematically reviewed for studies evaluating belzutifan in VHL-associated HBs. Outcomes included objective response rate, rate of dose reduction and treatment interruption due to adverse events, time to response (TTR), duration of response (DOR), tumor progression, and incidence of anemia. Analyses were performed using STATA 17. Results: Seven studies comprising 106 patients were included. Overall, 67% of patients achieved a therapeutic response (95% CI: 48-84; I2=65.4%). Dose reductions occurred in 19% (95% CI: 4-38; I2=70.6%) and treatment interruptions in 6% (95% CI: 0-25; I2=78.7%). The median TTR was 4 months, median DOR was 13 months, and tumor progression occurred in 2.8% of patients. Anemia occurred in 73.6%, with only 7.7% progressing to grade 3. Conclusions: Belzutifan demonstrates promising efficacy in VHL-associated HBs, achieving therapeutic responses and reducing tumor progression with minimal need for treatment interruption. Anemia is the most frequent AE but rarely progresses to grade 3; monitoring for transfusions and dose adjustment is recommended. Caution is warranted in interpreting pooled results given the high inter-study heterogeneity (I² > 60%), particularly for ORR, rate of dosage decrease, treatment interruption, and anemia. Future studies with larger cohorts are needed to improve reliability and generalizability.



Publikationsverlauf

Eingereicht: 12. August 2025

Angenommen nach Revision: 13. Oktober 2025

Accepted Manuscript online:
17. Oktober 2025

© . Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany